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Abstract The role of formula very low-energy diets (VLEDs, <800 kcal/day) and low-
energy diets (LEDs, 800–1200 kcal/day) within clinical practice has regained
attention over the last few years. Formula diets can achieve clinically significant
weight reduction in the short-term (3–5 months) and new evidence demonstrates
that long-term weight loss maintenance (up to 4 years) is achievable. Weight
reductions of between 10% and 15% bodyweight have been reported, which is
associated with clinically meaningful health outcomes in a number of obesity-
related co-morbidities including type 2 diabetes (T2D), obstructive sleep apnoea
and osteoarthritis. Recent evidence indicates that using a formula LED with a
weight loss maintenance programme can help people with overweight or obesity
and T2D achieve remission. Despite this, few healthcare professionals in the UK
routinely use LEDs. Concerns about adherence, risk of precipitating eating
disorders, safety, cost and long-term efficacy may, in part, contribute to their
under use. To help inform healthcare professionals on the use of formula diets
within clinical practice, this review examines the current evidence for the use of
VLEDs and LEDs for weight loss and weight loss maintenance, and in the
treatment of obesity-related co-morbidities, including T2D, osteoarthritis,
psoriasis, obstructive sleep apnoea and secondary coronary prevention, with a
particular focus on T2D remission.
Keywords: formula diets, low-calorie/energy diets, obesity, type 2 diabetes remission,
very low-calorie/energy diets, weight loss
Introduction
Obesity represents one of the greatest public health
challenges of modern times. In 2016, it was estimated
that globally, 1.9 billion adults were overweight and
650 million were obese (World Health Organization
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2018b), representing an overall prevalence of approxi-
mately 12% (Afshin et al. 2017). Obesity can con-
tribute to a greater risk of non-communicable diseases
(NCDs) including type 2 diabetes (T2D), ischaemic
heart disease, stroke and some cancers (Nyberg et al.
2018). With 71% of worldwide deaths attributed to
NCDs (World Health Organization 2018a), effective
treatment and management strategies for obesity and
its co-morbidities, specifically T2D, are key priorities
for healthcare systems worldwide.
Despite best efforts, the rising prevalence of obesity
and obesity-related co-morbidities has not yet been
adequately addressed with the tools currently avail-
able. In a systematic review of the effects of specialist
Tier 3 weight management interventions for adults in
the UK, weight reduction in the majority of studies
ranged between 2 and 6 kg (Brown et al. 2017a,b).
While a 5–10% bodyweight loss can have significant
health benefits, weight loss of this magnitude has been
suggested to be insufficient to give sustained and
noticeable benefits in those with greater body mass
indexes (BMI, ≥35 kg/m2), which are often associated
with serious medical conditions (SIGN 2010). Bari-
atric surgery remains the most effective treatment for
severe obesity and its co-morbidities (Colquitt et al.
2014), with weight reduction of 20–30% being
reported (Miras & le Roux 2013). However, not every
patient wishes to have surgery, there is a risk of com-
plications and access remains limited to <1% of eligi-
ble patients in the UK, far lower than other European
countries and the US (Welbourn et al. 2016). As yet
there is clearly an unmet need for cost-effective sus-
tainable weight loss methods to address the burgeon-
ing population of individuals with obesity and the
tsunami of T2D that is about to overwhelm healthcare
services worldwide.
Formula very low-energy diets (VLEDs) and low-
energy diets (LEDs) are specially formulated food prod-
ucts, usually in the form of liquid soups, shakes and
bars, and have been available in the UK for about
35 years (Leeds 2014). VLEDs provide fewer than
800 kcal/day (3347 kJ) and are designed to replace the
whole diet using 3–4 products per day (NIH 1993;
CODEX 1995; NICE 2014b); as such, they are defined
as a total diet replacement (TDR). In comparison, a
LED provides between 800 and 1200 kcal/day (3351–
5021 kJ) and can either be a TDR or the formula
products can be incorporated into modified conven-
tional meals as a partial diet replacement. Typically,
the TDR phase lasts 8–16 weeks within clinical trials
(Johansson et al. 2014a; Leeds 2014; Lean et al.
2017), although this has been extended to 20 weeks to
allow for greater weight reduction (Lean et al. 2017).
The National Institute for Health and Care Excellence
(NICE), however, recommends a maximum of 12
weeks of TDR at present (NICE 2014b), although
there is a lack of evidence for this time limit.
There is now increasing interest in the use of
VLEDs and LEDs in primary care and other therapeu-
tic settings driven by increasing evidence for their effi-
cacy and safety. Their capacity to facilitate weight
reductions that lie in the void between those achieved
through bariatric surgery and conventional diet inter-
ventions has been associated with clinically meaning-
ful outcomes for a number of obesity-related co-
morbidities (Garvey et al. 2016). Anxieties among
healthcare professionals about the potential risks of
rates of weight loss greater than 1 kg/week causing
excessive lean tissue loss and rapid weight regain seem
not to have been borne out in recent experimental
work (Purcell et al. 2014; Christensen et al. 2017a,b).
Greater rates of weight loss seem to be associated with
better dietary compliance, possibly because rapid
weight loss is highly motivating in some people and
has been shown to be associated with increased weight
maintenance (Wadden et al. 2011).
Formula VLEDs and LEDs have the potential to
make a meaningful contribution to meeting the global
challenge of obesity and its co-morbidities, the most
prevalent of which is T2D. This review will examine
the current evidence for the use of formula VLEDs
and LEDs in weight loss and treatments of obesity-
related co-morbidities, with particular focus on their
use in T2D remission. The review is narrative in nat-
ure, with the intention of identifying and discussing
relevant evidence within the area to help inform
healthcare professionals on the use of formula diets
within clinical practice. This is not a systematic
review, rather, studies were examined and critically
appraised to help clarify the current status of research
within the area of formula VLEDs and LEDs.
Weight loss on very low-energy and low-
energy formula diets
Formula VLEDs and LEDs have been shown to be
effective at promoting significant weight loss in the
short-term (up to 20 weeks) (Tsai & Wadden 2006;
Christensen et al. 2011; Brown et al. 2015). During
the TDR phase, individuals can typically lose between
10 and 16 kg or 10% and 15% of bodyweight
(Johansson et al. 2014a; Leeds 2014; Lean et al.
2017), with initial weekly weight losses varying
between 1 and 3 kg (Lean 2011; Leeds 2014; Brown
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et al. 2015). Weight loss has been shown to slow over
time, possibly due to reduction in resting metabolic
rate and reduced compliance to the formula diet (Hall
et al. 2011; MacLean et al. 2015; Vink et al. 2016).
Furthermore, there appears to be individual variability
in the total weight loss achieved, with men and those
with a higher initial bodyweight typically losing more
weight (Lean 2011; Bischoff et al. 2012; MacLean
et al. 2015).
In theory, due to the greater energy restriction,
VLEDs should produce greater weight losses than
LEDs. However, despite early studies showing greater
weight reduction with VLEDs compared with LEDs in
the short-term (Tsai & Wadden 2006), evidence indi-
cates weight losses are comparable at 12 months, with
the VLED group regaining 62% of the weight lost
compared to 41% in the LED group (Tsai & Wadden
2006). A more recent controlled trial showed no dif-
ference in the extent of weight loss after 16 weeks of
following either a VLED or a LED (Christensen et al.
2011).
Weight maintenance following very low-
energy and low-energy formula diets
Weight maintenance remains the most challenging
area of weight management in those with obesity. The
exact mechanisms that drive weight regain following
weight loss remain poorly understood but include
physiological, psychological and biological factors.
Weight regain following the initial TDR phase of for-
mula VLEDs and LEDs is common without additional
support. Often this occurs due to dropout from main-
tenance support, the rate of food reintroduction being
too rapid, environmental factors or patients not
addressing the reason for their initial weight gain.
Weight regain appears to be driven, in part, by
underlying biological changes that make an individual
feel hungrier and less satisfied after food, rather than
simply a lack of will power. Following weight loss on
a VLED, a compensatory increase in subjective hunger
has been reported and associated with higher circulat-
ing levels of ghrelin (a hunger hormone) and lower
circulating levels of peptide YY (PYY), leptin, amylin
and cholecystokinin (satiety hormones) compared to
baseline (Sumithran et al. 2011, 2013; Purcell et al.
2014). However, during the TDR phase of a VLED,
evidence suggests that patients experience less hunger
and greater satiety/fullness compared with baseline,
despite the significant energy restriction (Sumithran
et al. 2013; Gibson et al. 2014; Coutinho et al. 2017).
This, in part, is believed to be related to patients being
in a state of ketosis, which reduces hunger by lower-
ing concentrations of circulating ghrelin (Sumithran
et al. 2013). Emerging evidence suggests that these
acute compensatory weight loss induced changes in
gut hormones subside if the weight loss can be main-
tained (Iepsen et al. 2016), highlighting the impor-
tance of an effective weight loss maintenance
programme after a formula diet.
Recent well-controlled studies suggest that weight
loss maintenance is possible with the addition of sev-
eral key strategies (Mulholland et al. 2012; Chris-
tensen et al. 2014, 2017b; Johansson et al. 2014a).
For example, the continued use of formula products
either daily (1–2 products per day) or intermittently
(3 9 5-week periods each year) has been shown to aid
weight maintenance for up to 4 years (Christensen
et al. 2017b).
Pharmacotherapy has also been shown to have a
positive effect on weight maintenance following a
VLED (Johansson et al. 2014a) with Orlistat (a medi-
cation that prevents fat being absorbed from food)
producing a 2.4 kg greater weight loss at 22 months
compared with control. In another study of weight
maintenance following a VLED, those given a GLP-1
receptor agonist continued to lose weight, required
fewer meal replacement products to maintain their
weight and had smaller decreases in leptin and higher
PYY levels compared to those not on the GLP-1 recep-
tor agonist (Iepsen et al. 2015).
Physical activity is often recommended to aid weight
loss maintenance; however, following a VLED, evi-
dence indicates that the beneficial effect of physical
activity on weight maintenance is small (Fogelholm
et al. 2000; Borg et al. 2002). However, physical
activity may be beneficial in other ways. A recent sys-
tematic review of studies using either dual-energy X-
ray absorptiometry (DEXA) or underwater weighing
in those who achieved greater than 10 kg weight loss
following a VLED showed that median lean tissue loss
varied between 14% and 23.4%, depending on exer-
cise levels (Webster et al. 1984; Saris 2001; Chaston
et al. 2007). Both rigorous resistance and aerobic
exercise have been shown to limit lean tissue loss after
a VLED (Chaston et al. 2007; Snel et al. 2012a). Lar-
ger lean tissue loses have been seen in those with
higher BMIs at baseline, possibly due to the larger
energy deficit and insufficient dietary protein relative
to body mass. This suggests that in those with a body-
weight greater than 135 kg, particular attention
should be paid to the initial energy deficit achieved
and protein intake (Nielsen et al. 2016). Several stud-
ies have reported that following the use of formula
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diets, the ratio of lean to fat mass loss is approxi-
mately 25:75 (Saris 2001); if the ratio is greater than
this, reviewing protein intake and the rate of weight
loss might be beneficial.
Weight management clinicians have traditionally
suggested that losing weight in a slow and steady way
is preferable for long-term weight maintenance as
opposed to rapid weight loss, which is believed to
result in rapid weight regain. However, evidence has
recently emerged to suggest that this may not be the
case (Purcell et al. 2014; Coutinho et al. 2017). In one
study, individuals were supported to achieve a weight
loss of ≥12.5% bodyweight, either ‘rapidly’, using a
VLED for 12 weeks or ‘slowly’, using an energy defi-
cit diet (400–500 kcal/day deficit) over 36 weeks, to
assess the impact on weight regain (Purcell et al.
2014). Results indicated that the rate of weight loss
had no effect on the amount or rate of weight
regained over the subsequent 144 weeks. Furthermore,
the amount of weight loss achieved by any means in
the first year has been shown to be predictive of long-
term weight loss maintenance (Astrup & Rossner
2000; Wadden et al. 2011; Rolland et al. 2014). This
was evident in the Look Action for Health in Diabetes
(AHEAD) study that showed those achieving ≥10%
bodyweight loss (using a low-fat diet, meal replace-
ments and exercise) at 1 year had a 10.4 times greater
odds ratio of maintaining that loss at 4 years, com-
pared to those that lost less than 5% in the first year
(Wadden et al. 2011). The mechanisms driving this
effect remain unclear but may relate to the motivation
of actually losing significant weight.
The macronutrient composition of the diet after
initial weight loss may also play a role in weight loss
maintenance. This was assessed in a multicentre ran-
domised trial, the Diet, Obesity and Genes (Dio-
genes) study (Larsen et al. 2011; Aller et al. 2014).
Following a short 8-week weight loss phase using a
LED (800–1000 kcal/day) to achieve at least 8%
bodyweight loss, the study then assessed the effects of
four different maintenance diets, which varied in pro-
tein content and glycaemic index (GI) (high-GI/high-
protein; low-GI/high-protein; high-GI/low-protein;
low-GI/low-protein). At 6 months, the low-GI/high-
protein diet resulted in better weight loss mainte-
nance than the other three maintenance diets;
although at 12 months, only the protein content of
the diet was found to positively influence weight
maintenance (Larsen et al. 2011; Aller et al. 2014).
This suggests that diets higher in protein may aid
weight loss maintenance following a formula VLED
or LED.
The gradual reintroduction of food following a LED
or VLED is believed to assist with weight loss mainte-
nance (Leeds 2014; Brown et al. 2015). For example,
research has shown that reintroducing food over a 6-
week period resulted in significantly less weight regain
at 52 weeks compared with a reintroduction period of
1 week (3.9 kg vs. 8.2 kg, respectively) (Gripeteg
et al. 2010). In addition, reintroducing food over
6 weeks was associated with increased dietary
restraint (the tendency to eat less than desired) and
reduced external eating (the tendency to eat in
response to external cues such as the sight of food)
compared to reintroduction lasting only 1 week. It is
possible that the use of a partial formula diet during
the reintroduction phase will also enable individuals
to feel more in control of their food intake. Although
this is an area in need of further research, the food
reintroduction phase is believed to be an important
driver of weight loss maintenance following the TDR
phase (Lean et al. 2017).
Finally, the use of behaviour change techniques has
been shown to support weight maintenance following
a formula diet (Mulholland et al. 2012; Parretti et al.
2016). A recent systematic review compared changes
in weight loss using a behavioural programme alone
and a VLED plus behaviour change such as self-moni-
toring, planning ahead, goals setting and removing
food cues. At 1 year, the VLEDs combined with a
behavioural programme achieved a 3.9 kg greater
weight loss than the behavioural programme alone
(Parretti et al. 2016). Table 1 summarises the weight
loss, glycaemic control, surrogate markers of cardio-
vascular risk and attrition of the formula VLEDs and
LEDs.
Type 2 diabetes and very low-energy and
low-energy diets
Weight loss and type 2 diabetes
Weight loss remains the primary nutritional manage-
ment strategy for adults with overweight or obesity
and T2D (Dyson et al. 2018), with weight losses of
greater than 5% bodyweight leading to improvements
in glycaemia, blood lipids, insulin sensitivity and
blood pressure (Albu et al. 2010; Franz et al. 2015).
Intensive multicomponent lifestyle interventions con-
sisting of energy restriction, physical activity and
behaviour change, alongside patient education, remain
the cornerstone in the management of patients with
both obesity and T2D (Brown et al. 2017a) and have
been used to promote weight loss in people with T2D
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(Franz et al. 2015; Terranova et al. 2015). When com-
pared with standardised diabetes care in those with
T2D, using an intensive multicomponent lifestyle
intervention that included meal replacements, a low-
fat diet and physical activity has been found to pro-
duce greater weight loss, improvements in glycaemia
and T2D remission (Gregg et al. 2012; Esposito et al.
2014). There remains uncertainty regarding the most
effective dietary intervention to foster weight loss
(Nield et al. 2007), but what is key is choosing a life-
style change a patient is willing to stick to in the long-
term (Johnston et al. 2014).
The use of formula diets for those with T2D is not
a new practice. Prior to the recent resurgence in this
dietary approach, studies have shown formula diets to
be beneficial in this patient group. In a study on a
metabolic ward where patients with or without T2D
were provided with a VLED for 36 days, those with
T2D showed rapid improvements in glycaemic indices
and both groups showed normalisation of triglycerides
and total cholesterol, although those without T2D lost
more weight over this period (Henry et al. 1986). In
another study of patients with obesity and T2D, a
standard behavioural therapy programme was com-
pared with behavioural therapy plus an 8-week VLED
TDR phase. The use of a VLED plus behavioural ther-
apy produced a greater reduction in both fasting blood
glucose and glycated haemoglobin (HbA1c) levels than
the behavioural therapy alone, although the groups
did not differ in terms of weight loss (Wing et al.
1991), a finding that was replicated in those without
T2D (Wadden & Stunkard 1986). Finally, the inter-
mittent use of a VLED in patients with T2D and obe-
sity (2 9 12-week periods of 400–500 kcal/day)
produced greater weight loss than a food-based LED
(1000–1200 kcal/day), although fasting blood glucose
and HbA1c levels did not differ between the groups;
however, those who lost the most weight had the
greatest improvement in their HbA1c levels (Wing
et al. 1994).
Weight loss and type 2 diabetes remission
The idea that T2D can be put into remission using
dietary methods is not new. In an ancillary analysis of
the Look AHEAD cohort, subjects in the intensive
multicomponent lifestyle intervention group were
more likely to experience T2D remission (11.5%, par-
tial or complete) compared with those who received
standardised care (2%). However, rates of remission
declined over the follow-up period, with only 7%
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multicomponent lifestyle intervention group compared
with none in the standard care group (Gregg et al.
2012). In another study (Esposito et al. 2014) that
compared a low-carbohydrate Mediterranean diet to a
low-fat diet, T2D remission was reported in 14.7% at
1 year in the low-carbohydrate Mediterranean diet
group compared with 4.1% in the low-fat diet group
(Esposito et al. 2014). More recently, a non-rando-
mised, controlled study using a novel remote care
model, which included a well-formulated ketogenic
diet compared with usual care, showed the ketogenic
diet achieved T2D remission in 25% of participants
compared with no cases in the usual care group (Hall-
berg et al. 2018). Similar to the results of the Look
AHEAD trial, remission rates reduced over time in
both studies (Esposito et al. 2014; Hallberg et al.
2018).
Evidence suggests that there is a need for 15 kg
weight loss to induce T2D remission in those with
recently diagnosed T2D (Dixon et al. 2008; Lean
2011; Lean et al. 2017). However, weight loss inter-
ventions in patients with obesity and T2D typically
achieve only 2.4–8.5 kg reduction in bodyweight, even
in clinical trials (Franz et al. 2015). This raises the
question of whether current standard care is able to
produce the weight loss required to bring about T2D
remission in a significant number of patients. Bariatric
surgery remains the most effective treatment for both
obesity and T2D (Colquitt et al. 2014). Weight losses
of between 20% and 35% of bodyweight have been
reported 2 years after bariatric surgery (Miras & le
Roux 2013), with between 30% and 60% of patients
achieving T2D remission (Rubino et al. 2017). These
figures, however, vary with operation type and weight
loss and glycaemic control deteriorates over time in a
substantive number of patients (Yu et al. 2015;
Schauer et al. 2017). The exact mechanisms which
drive improvements in, and remission of, T2D follow-
ing bariatric surgery remain to be fully understood,
although are hypothesised to include alterations in gut
hormones, bile acid changes, adaptions in the micro-
biome and changes in food preferences and smell
(Miras & le Roux 2013; Batterham & Cummings
2016). Recent evidence points towards the acute
energy restriction that occurs immediately following
bariatric surgery playing a pivotal role in the early gly-
caemic improvements seen in both biliopancreatic
diversion (BPD) and Roux-en-Y gastric bypass
(RYGB) (Jackness et al. 2013; Lips et al. 2014), which
occurs prior to any changes in bodyweight or alter-
ations in plasma GLP-1 levels (Steven et al. 2016b).
With only a fraction of individuals accessing surgery,
there is a need for other treatment options to help
achieve clinically relevant weight loss that may bring
about T2D remission. Formula VLEDs and LEDs are
considered to have great potential to fill this gap
(Brown et al. 2015).
Type 2 diabetes remission using formula diets
The Twin Cycle hypothesis was first reported in 2008
and proposed that fat deposition, specifically within
the pancreas and liver, was key to the aetiology of
T2D (Taylor 2008). It is postulated that a positive
energy balance causes infiltration of fat into the hepa-
tocytes and pancreatic islet cells, which, in turn, drives
two corresponding metabolic cycles, causing a reduc-
tion in hepatic insulin sensitivity and suppression of
first phase insulin response (initial release of insulin
following nutrient ingestion), respectively (Lim et al.
2011), resulting in the development of T2D. The idea
of fat infiltrating the pancreatic beta cells is not new,
with first descriptions over 20 years ago in rat models
of T2D (Lee et al. 1994; Unger 1995). Within this
model, pancreatic fat was assessed and it was shown
that the peak accumulation of fat in the pancreatic
islet cells corresponded with the development of
hyperglycaemia, reduction in insulin secretion and
development of overt T2D (Lee et al. 2010). This sug-
gested that assessing fat in the human pancreas may
help predict risk of T2D; however, due to difficulties
with non-invasive quantification of fat in human islets
cells, this has not been possible to assess until rela-
tively recently (Tushuizen et al. 2007; Lingvay et al.
2009; Lim et al. 2011).
The first study to assess the Twin Cycle theory in
humans was the COUNTER acting Pancreatic inhibi-
tion of Insulin secretion by Triglycerides (Counter-
point) proof-of-concept study, which involved 11
patients with obesity and recently diagnosed T2D
(<4 years) following a VLED for 8 weeks. After com-
pleting the diet, their fasting blood glucose was nor-
malised (<7 mmol/l), in addition there was a
normalisation of hepatic insulin sensitivity and return
of first phase insulin compared to age- and weight-
matched controls (Lim et al. 2011). These improve-
ments corresponded with a reduction in liver and pan-
creatic triacylglycerol levels. Although this is not
considered full T2D remission, it showed for the first
time that acute energy restriction using a formula
VLED influenced two key features of T2D.
This proof-of-concept study was proceeded by the
Counteracting BetA cell failure by Long-term Action
to Normalise Calorie intake (Counterbalance) study
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on 30 subjects from the same group with either short
duration (<4 years) or longer duration of T2D
(>8 years). This study aimed to assess whether nor-
malisation of fasting plasma glucose (<7 mmol/l) fol-
lowing a VLED was maintained during weight
stability at 6 months. In those with T2D for more
than 8 years, only 50% achieved a fasting plasma glu-
cose of <7.0 mmol/l at 8 weeks, without any other
anti-diabetic medication, compared with 87% in those
with T2D duration of <4 years (Steven & Taylor
2015). Despite this difference, significant improve-
ments were reported in general health, blood pressure
and lipid profile in all participants. The second paper
from the Counterbalance study demonstrated that
after the VLED and once patients had returned to an
isocaloric diet, normalisation of fasting plasma glucose
was maintained for 6 months in 12 subjects (40%),
who were defined as ‘responders’ (Steven & Taylor
2015; Steven et al. 2016a). The responders had lower
HbA1c/fasting glucose and higher plasma insulin
levels, were younger, had a lower body mass, shorter
T2D duration, were on fewer medications and, impor-
tantly, had lower levels of pancreatic fat (Steven et al.
2016a). Although these data suggested that T2D could
be put into remission with acute energy restriction,
due to methodological weaknesses that included lack
of controls, selection bias and small participant num-
bers, more studies were required to inform clinical
practice.
Many of the questions posed within these initial
studies have now been addressed with the recently
published Diabetes in Remission Clinical Trial
(DiRECT) (Lean et al. 2017). This trial was designed
to answer whether or not using a formula LED, fol-
lowed by a long-term programme of weight loss main-
tenance in primary care, would result in remission of
T2D in those diagnosed with T2D in the previous
6 years, and if a 15 kg weight loss was possible in pri-
mary care (Lean et al. 2017). T2D remission, defined
as having an HbA1c <6.5% (48 mmol/mol) and off
all diabetes medication for at least 2 months from
baseline to 12 months, and 15 kg weight loss were the
primary end points.
In this randomised control trial (RCT), 306 partici-
pants with T2D were recruited from 49 general prac-
tices and randomised to either best practice NHS care
alone (control group) or best practice NHS care plus
an intensive structured weight management pro-
gramme (intervention group, Counterweight-Plus
weight management programme). The intervention
group received a formula LED TDR (825–853 kcal/
day) for 3–5 months, depending on weight loss,
followed by stepped food reintroduction (2–8 weeks)
and then a structured weight loss maintenance pro-
gramme. At 12 months, in an intention to treat analy-
sis, 46% of participants achieved T2D remission in
the intervention group compared to 4% in the control
group. In addition, 24% achieved ≥15 kg weight loss
in the intervention group compared to none in the
control group, with overall mean weight reduction of
10 kg in the intervention group and only 1 kg in the
control group. Interestingly, increased weight loss was
associated with a higher rate of T2D remission: 73%
of those achieving ≥10 kg weight loss went in T2D
remission, while 86% of those with ≥15 kg weight
loss achieved remission. This study clearly showed
that T2D remission could be achieved for a large per-
centage of people with T2D within a primary care set-
ting and should be considered a goal of treatment in
those with recently diagnosed T2D (Diabetes UK
2018).
A subgroup of patients from the DiRECT study
were assessed to explore pathophysiological differ-
ences between those that did (responders) and did not
(non-responders) achieve T2D remission (Taylor et al.
2018). The results showed that the early and sustained
improvement in beta cell function and the ability to
recover first phase insulin response as key to T2D
remission (Taylor et al. 2018). In addition, responders
had shorter duration of T2D, lower HbA1c levels,
higher fasting plasma insulin levels and higher plasma
alanine aminotransferase levels than non-responders.
The use of formula diets in those patients with
T2D and treated with insulin is less well studied and
the benefits not yet fully established. Studies in this
cohort have focussed on the use of formula VLEDs
and have shown significant improvements in weight
loss, low-grade inflammatory markers, body composi-
tion, surrogate markers of CVD including blood pres-
sure, plasma lipids, quality of life and glycaemic
control (Christiansen et al. 2000; Jazet et al. 2005,
2007, 2008; Snel et al. 2011, 2012a,b,c). However, it
should be noted that these studies lacked control
groups (that did not include a VLED) and included
only small numbers of subjects in whom all diabetes
medication including insulin was ceased, which indi-
cates that the subjects had residual pancreatic func-
tion, something that not all advanced T2D patients
will have, therefore questioning the validity and
transferability of the findings. Despite these method-
ological issues, these studies hint that using a formula
VLED may be of benefit within this patient group,
although high quality research is needed to confirm
these findings.
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Despite the recent resurgence of research on formula
diets and T2D within clinical practice, questions
remain regarding how best to pragmatically translate
the research findings into current healthcare practices.
With limited healthcare resources available to manage
and treat those with T2D and obesity, offering a for-
mula VLED or LED to all may not be financially
viable. A targeted, individualised approach may be
more feasible, but future research is necessary to iden-
tify those individuals with T2D that are most likely to
respond positively to a formula diet.
The management of medication is an important
consideration and should be appropriately managed
by an individual’s medical team both during and fol-
lowing formula diets. Oral hyperglycaemic medica-
tions (sulphonylureas) and insulin requirements
require significant reductions to reduce the risk of
hypoglycaemia, with the suggestion of a pre-emptive
reduction of insulin by 25% at the commencement of
a VLED (Haslam et al. 2010). Anti-hypertensive medi-
cation should also be reviewed to avoid low blood
pressure, which is a common side effect in those using
formula VLEDs or LEDs. Protocols for managing
T2D and blood pressure medications when using a
formula diet are published in the DiRECT study pro-
tocol and the Doctor Referral of Overweight People
to Low-Energy total diet replacement Treatment
(DROPLET) study paper (Leslie et al. 2016; Astbury
et al. 2018). Furthermore, it is essential that patients
that do achieve T2D remission should continue to be
monitored for T2D-related complications and also
deterioration of glycaemic control at least annually
(Diabetes UK 2018).
The cost-effectiveness of formula diets for treat-
ment of T2D and whether they are a viable option
within clinical practice are important considerations.
A recent cost analysis of the intervention used in the
DiRECT trial showed the total cost per intervention
participant was £1223, with formula products and
practitioner visits making up the majority of costs
(95%) (Xin et al. 2018). It was estimated that each
case of T2D remission would cost on average £2564
compared with £846 per participant in the control
group receiving standard NHS care. It is clear from
this analysis that the DiRECT intervention is more
expensive to deliver than standard care, but when
compared with the cost of the Look AHEAD inter-
vention (US$2865 per participant) (Rushing et al.
2017) and bariatric surgery, which is estimated to
have a mean cost of US$14 389 per participant
(Doble et al. 2017), this is clearly an attractive
option.
Formula diets in the management of other
obesity-related co-morbidities
Osteoarthritis
With ageing populations that are heavier than in the
past, the prevalence of osteoarthritis (OA) is increas-
ing (Cross et al. 2014). There is currently no medica-
tion or other intervention proven to slow the disease
process. Treatment is palliative until surgical joint
replacement, total or partial, becomes necessary.
Weight reduction is a core feature of osteoarthritis
guidelines (NICE 2014a) but is difficult to achieve in
those with limited mobility and who may have dis-
turbed sleep (due to pain) and depression.
Early studies suggested a role for TDR as therapy
for OA (Aaboe et al. 2011; Bliddal et al. 2011) and
were followed soon afterwards by a definitive clinical
trial at the Parker Arthritis Institute in Copenhagen.
The two phase Cartilage and Osteoarthritis weight
loss trial (CarOT) recruited obese people with knee
OA for an initial comparison of weight loss with
8 weeks on either a VLED (415 kcal/day) or a LED
(810 kcal/day) followed by stepped food reintroduc-
tion up to 1200 kcal/day by 16 weeks (Christensen
et al. 2011, 2014, 2017b). The same participants then
entered the second phase of the CarOT which was an
RCT of weight loss maintenance for 12 months com-
paring three groups: (1) one meal replacement product
daily with conventional food; (2) leg muscle strength-
ening exercises with conventional dietary restriction;
and (3) control (no intervention).
All participants in the CarOT were then invited to
enter a third RCT: the ‘long-term intervention with
weight loss in patients with concomitant obesity and
knee OA’ (LIGHT) trial, a 3-year RCT comparing
one meal replacement product daily with intermittent
use of an 810 kcal/day TDR for 5 weeks every
4 months. One hundred and ninety-two patients (aver-
age weight 103 kg, BMI 37 kg/m2) entered phase one:
average weight loss at the end of the 16-week period
was 12 kg after the LED and 13 kg after the VLED.
(Christensen et al. 2011). After 1 year of the second
phase maintenance intervention, the diet group (one
meal replacement product/day) maintained 11 kg
weight loss on average, the exercise group 6 kg and
the control group 8 kg (Christensen et al. 2014).
Osteoarthritis symptom scores were significantly
improved (less pain) after the initial weight loss and
after 1-year maintenance (no difference between the
groups). Lean mass losses at 1 year were between 9%
and 13%, lower than expected possibly due to
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increased activity. Biomechanics studies on the same
subjects showed that each 1 kg weight reduction
reduced the peak knee load by 2.2 kg (Aaboe et al.
2011). Both interventions used in the LIGHT 3-year
maintenance study resulted in maintenance of the ini-
tial weight loss of 10% achieved in the CarOT in 108
out of 153 participants who managed to complete the
full 3-year study, with no significant differences
between the groups (Christensen et al. 2017b). Fur-
thermore, reduction of symptom scores and reduced
blood pressure were maintained, demonstrating the
effectiveness of such a programme on OA. Imaging
studies on subsets of these participants in the CarOT
and LIGHT studies showed that inflammation in the
Hoffa’s fat pad (under the patella) (Ballegaard et al.
2014) and synovial membrane (Riis et al. 2016) was
related to the severity of knee pain, suggesting that
reduction of inflammation associated with weight loss
is the mechanism that results in pain reduction.
A large-scale observational study undertaken in
Australia on 1383 people (average BMI 34 kg/m2)
with knee OA explored the effects of an 18-week
healthy weight loss programme and allowed a thresh-
old for symptomatic benefit to be established: partici-
pants needed to achieve more than 7.7% bodyweight
loss in order to achieve clinically important symptom
improvement in symptoms of knee OA (Atukorala
et al. 2016). Just over half the participants achieved at
least 7.7% weight loss. There was an option to use
two meal replacement products daily in the first
6 weeks but the weight loss programme was otherwise
based on conventional foods. In the study by Chris-
tensen et al. (2011), following 8 weeks of TDR, the
initial weight loss of 12% resulted in rapid knee OA
symptom improvement (good responses in >60% of
participants). Participants were highly motivated to
continue the diet by the reduction of pain. Compliance
was impressive (dropout rate was 14 out of 192,
about 7%) and more than 50% managed to maintain
around 10% weight loss with symptom improvement
for 4 years. Weight loss and subsequent maintenance
is a surrogate marker for dietary energy intake and
energy expenditure, a sustained change of which
drives reduction of pro-inflammatory and pro-insulin
resistance signalling (Geyer et al. 2016). This was
demonstrated in a study of 43 healthy participants
with obesity to assess the effect of a TDR on blood
proteins (Geyer et al. 2016). Following the initial
TDR, there was a 12% weight loss, which was tightly
maintained at 12 months. Ten out of 400 proteins
associated with the pro-inflammatory state showed a
prompt reduction during the initial weight loss and
then continued to fall throughout the 12-month
weight maintenance period. Four proteins associated
with insulin resistance also fell promptly and remained
low throughout the year.
There would seem to be few contraindications to
rolling out an effective intensive lifestyle intervention
for the millions of people with knee OA whose quality
of life is seriously impaired by pain, poor sleep and
immobility when evidence indicates that TDR is an
effective treatment for knee OA in a high proportion
of those with this condition. That this has not been
done might reflect healthcare practitioners’ lack of
experience with using TDR, long-held myths about
adverse effects of TDR and innate conservatism and
resistance to change in medical practice. Nevertheless,
further investigation is needed into the reasons,
beyond dietary compliance, why some people with
knee OA respond better than others to TDR (disease
stage and variation in ‘metabolic burden’ are likely
influences on symptom response). The evidence on
weight loss in knee OA should not be extrapolated to
OA in other joints, but anecdotal evidence hints that
weight loss may improve stiffness and reduce pain in
hand OA. A randomised trial of weight loss with
TDR in hand OA is about to start at the Parker Insti-
tute in Copenhagen.
Obstructive sleep apnoea
Obstructive sleep apnoea (OSA) increases risk of
stroke and myocardial infarction through raised blood
pressure and blood pressure fluctuations, among other
variables. OSA is associated with obesity in some peo-
ple and represents an additional problem for many
people with T2D. As a previously neglected obesity
co-morbidity, OSA is now identified more commonly
and is treated with continuous positive airways pres-
sure or similar devices.
The evidence for a beneficial effect of weight loss
among OSA patients has long been recognised in
Scandinavia but even after publication of two high-
quality studies (Johansson et al. 2009, 2011), little has
changed in the use of weight reduction for OSA man-
agement in the UK, again perhaps reflecting healthcare
practitioners’ lack of experience with using TDR. The
first of these studies (Johansson et al. 2009) was in 63
men with moderate or severe OSA who were ran-
domised to control (no treatment) or a VLED
(550 kcal/day) over 9 weeks. Those in the VLED
group showed an average weight loss of 18.7 kg with
26 out of 30 demonstrating improved OSA scores (five
were ‘cured’ of their OSA), in comparison to the
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control group who showed an average weight gain of
1 kg with mostly unchanged symptoms of OSA,
though 5 out of 33 did show improvements.
Johansson et al. (2011) then offered the control
group the same VLED programme and followed all 63
participants for 1 year at which point 30 out of 63 no
longer required continuous positive airways pressure,
with six of them being in full OSA remission. Those
who completed the full programme maintained 17 kg
weight loss, while weight maintenance was 12 kg on a
basal observation carried forward basis over 1 year.
Interestingly, those who lost most weight or who had
the most severe OSA at baseline gained the most bene-
fit from this intervention (Johansson et al. 2011).
Several other studies have also showed that using
VLEDs or LEDs in patients with obesity results in
clinically relevant improvement in weight loss,
Apnoea/Hypopnoea Index (AHI), oxygen desaturation
index and resolution of OSA, with reduction of AHI
equating to less than five events/hour (Kajaste et al.
2004; Tuomilehto et al. 2009; Nerfeldt et al. 2010).
Cardiovascular and cardiac rehabilitation
Data from systematic reviews (Mulholland et al.
2012; Parretti et al. 2016) have suggested that the use
of formula VLEDs might reduce CVD risk with
improvements seen with surrogate CVD risk markers
including blood pressure, lipid profile and glycaemic
control.
One pilot study (Olsen et al. 2015) compared TDR
with exercise training (aerobic interval training) on
coronary microvascular function in women with coro-
nary artery disease and showed that both interventions
significantly improved microvascular function. The
findings suggested that achieving an initial bodyweight
loss of 10% followed by a weight maintenance pro-
gramme with aerobic interval training gave superior
outcomes at 1 year compared to aerobic interval train-
ing followed by dietary guidance with continued aero-
bic interval training. The initial weight reduction with
TDR was associated with increased insulin sensitivity
(Pedersen et al. 2015), a less atherogenic blood lipid
profile (Pedersen et al. 2016), a relatively small loss of
lean mass, and improved cardiovascular fitness com-
pared to the initial aerobic interval training pro-
gramme followed by aerobic interval training and
dietary advice. Larger weight losses are not a standard
component of cardiac rehabilitation and further large-
scale trials are needed to determine whether weight
loss with TDR should be a component of cardiac
rehabilitation. A further trial has been designed.
Psoriasis
Most inflammatory changes are invisible, though may
be marked by symptoms such as pain and stiffness. In
psoriasis, an autoimmune disease characterised by
patches of red, thickened and scaly skin, the extent
and severity of inflammatory change in the skin can
be assessed by clinical examination. With evidence
showing marked improvement in inflammation follow-
ing a VLED (Geyer et al. 2016), it is possible that this
approach may help with psoriasis symptoms. A pilot
RCT by Jensen et al. (2013) followed by a 1-year
observational period showed that average weight loss
of 15 kg in people with psoriasis could be achieved
with a VLED TDR and about two-thirds of that
weight loss was maintained for a year. The skin scores
improved in a clinically meaningful way, and those
improvements were largely maintained in those who
stayed in the programme (Jensen et al. 2016). Though
only a pilot trial, this work was recognised as a land-
mark contribution to psoriasis management for which
effective diet, weight and lifestyle management inter-
ventions are lacking. In view of the complex interplay
of genetic, environmental and psychological factors in
psoriasis (Jensen & Skov 2016), it was unforeseen that
weight loss alone would deliver such a dramatic effect
(though the epidemiology of psoriasis does show a
clear effect of bodyweight on disease risk) and these
preliminary findings should be followed by a multicen-
tre large-scale clinical trial. People with OA and psori-
asis have adverse cardiovascular risk profiles and both
the weight loss studies in psoriasis (Jensen et al. 2014)
and OA (Christensen et al. 2013) showed improve-
ments in cardiovascular risk factors.
Use of formula very low-energy and low-
energy diets in primary care settings
Clinical trial evidence for the efficacy of formula diet
programmes has largely been gathered in research set-
tings in major institutions or primary healthcare set-
tings. Global demand for weight loss exceeds the
capacity for secondary healthcare services to deliver
formula diets, therefore offering them in primary care
is a potential solution. In the DROPLET pragmatic
RCT (Astbury et al. 2018), 278 participants were
recruited from GP practices. They were randomised to
either a LED TDR (810 kcal/day) for 8 weeks fol-
lowed by 4 weeks of food re-introduction and then a
12-week weight loss maintenance programme deliv-
ered by a commercial counsellor in the community, or
to usual care provided by local practice nurses. At
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12 months, the LED TDR group lost on average
10.7 kg (10% bodyweight) compared with 3.1 kg in
the control group (see Fig. 1). Almost half (45%) of
people in the LED TDR group achieved ≥10% weight
loss compared to 15% in the control group. The
greater weight loss achieved and maintained following
TDR was associated with significantly greater
improvements in levels of HbA1c, fasting blood glu-
cose, and blood triglycerides, and insulin sensitivity
and quality of life compared to usual care. When con-
tact with the counsellor was reduced, patients regained
weight, which is not unique to formula diets. This
highlights the importance of a structured weight loss
maintenance programme to minimise weight regain.
Prescribing challenges related to reduction of medica-
tion dosage were well met by GPs with the help of
medication protocols (Primary Care Sciences Oxford
2018). The study by Asbury et al. concluded that a
TDR programme is an acceptable, safe and effective
treatment for obesity in primary care and demon-
strated that an alternative, scalable model of delivery
for a formula TDR programme was possible. A full
health economics analysis will be published but a pre-
liminary account indicated that TDR is cost-effective
by usual NICE standards (£20 000 per quality-
adjusted life year) (Kent et al. 2018).
Other studies that have looked at the application of
formula LEDs in primary care for obesity treatment
are the two service evaluations of the ‘Counterweight-
Plus’ programme (Lean et al. 2013; McCombie et al.
2018). In the initial feasibility study, at 12 months, 68
of the initial 91 patients achieved a mean weight
loss of 12.4 kg with 33% achieving ≥15 kg weight
loss at 12 months. Following this study, the full
Counterweight-Plus programme was commissioned
and recent 4-year audit data have been published
(McCombie et al. 2018). Two hundred and eighty-
eight patients commenced the programme. At
12 months, in an intention to treat analysis, subjects
had achieved a mean weight loss of 10.5 kg, with
22.1% achieving ≥15 kg weight loss and 31.8%
achieving >10 kg weight loss. Weight loss at 3 and
6 months was positively correlated to weight loss at
12 months, showing that helping subjects achieve a
high initial weight loss may benefit long-term mainte-
nance. Attrition within this evaluation was 44.2%,
slightly higher than that reported in previous studies
using formula diets but typical of the follow-up rate
found in clinical practice (Brown et al. 2017b). Despite
some limitations in these service evaluations studies,
including the lack of randomisation, possible selection
bias, and significant dropout, taken with the DRO-
PLET study findings, they show that for motivated
patients a formula LED approach combined with a
weight loss maintenance programme can achieve clini-
cally significant weight loss in primary care.
Nutritional issues with formula diets
Questions still remain about the possible detrimental
effects of formula diets on vitamin and mineral status,
particularly during the weight loss phase and in those
Figure 1 Estimated weight change over 12 months in the intention to treat population of the DROPLET trial. Weight loss shown in kg and as percentage of
bodyweight. Figure redrawn from Astbury et al. (2018) with permission. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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with a higher BMI (Damms-Machado et al. 2012;
EFSA NDA Panel 2015). However, in studies assessing
micronutrient quality in popular energy-restricted diets
including the South Beach, Atkins and Dietary
Approaches to Stop Hypertension (DASH) diets, it
was shown that these fail to meet US Reference Daily
Intake (RDI) for many and, in the case of some diets,
all micronutrients analysed (Calton 2010; Gardner
et al. 2010). As three to four formula TDR products
per day provide 100% of the Population Reference
Intakes (PRI) for minerals and vitamins, this approach
may well provide a more balanced micronutrient sup-
ply than conventional weight loss diets.
Data on micronutrient status of those following a
formula diet are limited. One study demonstrated that
a formula LED resulted in no change in ferritin levels,
an increase in vitamins D and B12 levels and a
decrease in parathyroid hormone (reflecting reduced
secondary hyperparathyroidism caused by vitamin D
deficiency) (Christensen et al. 2013). However,
another study suggested that the vitamins and miner-
als provided in a formula LED were insufficient to
meet demands of an obese person (Damms-Machado
et al. 2012); although, to note, nutritional deficiencies
were present before the study and this may have influ-
enced the findings. There is clearly a need for more
research in this area to understand the requirements
for vitamins and minerals in people with obesity, par-
ticularly during the weight loss phase and in those
with higher BMIs.
Adverse events and attrition
Adverse event frequency is more extensively docu-
mented than 4 years ago (Leeds 2014). The largest
dataset from the Prevention of diabetes through life-
style intervention and population studies in Europe and
around the world (PREVIEW) study (Christensen et al.
2018) (weight loss with TDR in 2224 participants with
pre-diabetes) showed that the most common com-
plaints were constipation (15%), fatigue/muscle weak-
ness (9%), headache (8%) and dizziness (4%); in the
DROPLET trial, the same side effects were reported
(in 138 participants) but at half that frequency (8%,
5%, 3% and 2%, respectively) (Astbury et al. 2018).
Constipation has long been recognised as a conse-
quence of the large reduction in residual substrate
entering the colon for fermentation and stool-bulking
when using TDR. This can be overcome by providing
additional stool-bulking dietary fibre (e.g. Psyllium
husk) from the commencement of the diet, especially in
those with a previous history of constipation,
diverticular disease, diverticulitis or anal pathology.
The fatigue or muscle weakness is a physiological
response consistent with changes in muscle strength
reported by Henriksen and colleagues, a subset of par-
ticipants in the weight loss with TDR in people with
knee OA trial (CarOT). Absolute muscle strength
decreased by 3–4% although ‘body mass normalised’
muscle strength increased by 11–12% (Henriksen et al.
2012). Potential users of TDR need to be warned of
the likelihood of these effects, particularly dizziness
which may be more troublesome in the elderly and
those treated with anti-hypertensive medications. Blood
pressure is reduced rapidly in some individuals, and
there is a risk of postural hypotension. Those with
hypertension should be warned about dizziness on
standing up, monitored more frequently than weekly
initially and have their medications reviewed by their
GP promptly. TDR caused gout at a rate of less than
one in 1500 in women and one in 120 in men in the
PREVIEW study (Christensen et al. 2018). There were
no identified cases of gallstones in 2224 participants in
the PREVIEW study but a large study from Sweden
that showed the rate for hospitalisation for investiga-
tion and treatment of gallstones was three times higher
after a VLED than after a 1200 kcal/day LED,
although most cases occurred in the food re-introduc-
tion phase (Johansson et al. 2014b). Thus, it is wise to
advise that there is a small risk of a gallstone event
after a VLED and possibly after a LED.
A relatively high proportion of participants are
retained in TDR trials. In the LIGHT long-term
weight maintenance knee OA trial (Christensen et al.
2017b), 109 out of 153 entrants (71.2%) stayed in the
programme for 3 years perhaps motivated by their
preceding 10% weight loss that improved their mobil-
ity and reduced pain. The provision of TDR products
and frequent contact with a healthcare professional
certainly also played a part in this low attrition rate.
In contrast, in the PREVIEW study of 1854 partici-
pants with pre-diabetes who started the 3-year con-
ventional diet programme, 962 (52%) stayed in the
programme for 3 years with less frequent contact and
only conventional diet and lifestyle variables (Tucker
2018). Symptomatic improvement, especially in a
chronic degenerative condition, may be a strong moti-
vator for long-term compliance.
Patient views and experiences of formula
diets
Currently, the assessment of patients’ views and expe-
riences of formula diets is limited within the scientific
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literature. A recent systematic review of the qualitative
research on the experiences of people using VLEDs for
weight loss identified only three qualitative studies
(Ostberg et al. 2011; Love et al. 2016; Rehackova
et al. 2017) that explored in-depth, subjects’ experi-
ences following a VLED (Harper et al. 2018). They
reported that the VLED was easier to adhere to than
initially thought. The rapid weight loss, feeling less
hungry and the ease of use of the diet facilitated sub-
jects’ adherence. Furthermore, it gave them new
insights into their relationship with food, which sup-
ports anecdotal reports from clinical practice. Other
key factors identified that aided adherence included
avoidance of tempting situations and environments
(e.g. avoiding socials events and triggers for food
consumption), planning ahead and self-distraction
techniques. Therefore, educating subjects about beha-
vioural techniques that could help them manage
potential triggers for food consumption prior to start-
ing a formula diet may aid weight loss and long-term
maintenance. One key element reported by the sub-
jects was the inclusion of group support sessions.
Subjects reported that these provided a sense of com-
munity and also competition with each other, which
was not possible with the one-to-one appointments.
This is an important consideration when thinking
about using formula diets in clinical practice.
In addition to the studies included in the systematic
review by Harper et al. (2018), a recent study
explored the psychosocial determinants of maintaining
weight loss following a formula diet in subjects who
were classified as either ‘weight reducers’ (>3% weight
loss) or ‘weight regainers’ (>3% weight gain) at
52 weeks (Christensen et al. 2017a). The ‘weight
reducers’ reported having a structured meal pattern,
no comfort eating and less psychological stress com-
pared with the ‘weight regainers’ (Christensen et al.
2017a). In addition, three key ingrained habits were
identified which were calorie counting, choosing foods
based on their nutrient content and using self-monitor-
ing tools, which the authors termed the ‘instrumentali-
sation of eating behaviour’ (Christensen et al. 2017a).
These three habits were similar to those factors identi-
fied in the National Control Weight Registry, which
included eating a low-energy diet and self-monitoring
weight (Wing & Phelan 2005), suggesting that these
may be key to weight loss maintenance.
Gaps in knowledge
Despite increasing evidence for the efficacy of LEDs
and VLEDs to achieve clinically significant weight
loss, there are several areas where more work needs to
be undertaken. There remains significant heterogeneity
in the literature with regard to study methodology,
particularly the time scale of the TDR phase, how best
to reintroduce food following TDR, the most effective
way to manage weight loss maintenance and in which
circumstances a VLED or LED is used. As such, it cur-
rently remains challenging to develop best practice
guidelines.
Rescue packages, which involve temporary use of
the TDR phase or intermittent use of the formula pro-
duct, have been shown to aid weight maintenance
(Christensen et al. 2017b; Lean et al. 2017). However,
when and how best to use rescue packages still
requires further research.
Two areas of particular interest for the use of for-
mula diets are chronic kidney disease (CKD) and non-
alcoholic fatty liver disease (NAFLD), both of which
are highly prevalent within the obese and T2D patient
population and can benefit significantly from weight
loss. At present, however, there is limited evidence to
support the use of formula diets within clinical prac-
tice for these conditions (Mulholland et al. 2012;
Rolland et al. 2013; Brown & Taheri 2018).
Although defined within legislation, some aspects of
the recommended nutritional composition of formula
diets are based on weak experimental evidence. There
is a clear need for further clinical studies to determine
optimal diet composition during rapid weight loss in
the TDR phase, with special reference to protein and
lean mass reduction, essential fatty acid requirements
and micronutrients, with studies on those with a BMI
greater than 50 kg/m2 particularly needed. More
research is also needed on the optimal macronutrient
composition to aid weight maintenance, medication
prescribing practices both on commencing weight loss
and on reintroducing conventional food, and optimal
levels of physical activity during both weight loss and
weight loss maintenance.
Although the DiRECT study was highly effective in
achieving clinically significant outcomes, several ques-
tions remain unanswered. It remains unclear whether
the use of the Counterweight-Plus Programme is a pre-
requisite to achieving the same clinical outcomes or
whether this could be achieved within current clinical
practice with a different structured programme. As
each subject received around 20 contacts in the initial
12 months of the DIRECT trial, this is likely not to
be achievable in the majority of clinical services. Fur-
thermore, the DiRECT study was limited to those
with T2D for less than 6 years, meaning that this diet-
ary method cannot, at present, be recommended to
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people with more advanced T2D or those treated with
insulin. However, research within this patient popula-
tion is now complete and due for publication in the
near future. With over three million people living with
T2D in the UK, gaining a greater understanding of the
characteristics of those individuals that achieve T2D
remission on a formula diet will aid a more focussed
approach; the pathophysiologic studies from DiRECT
have highlighted some key factors, the challenge now
is how best to translate these findings to clinical prac-
tice. In addition, there is need for the DiRECT study
to be replicated in a more ethnically diverse popula-
tion, as nearly all patients were white British (98.5%),
meaning results at present are not generalisable to the
wider British population with T2D. It is understood a
study with these objectives is currently underway.
Finally, as yet, the long-term effects of a LED TDR
programme on T2D remission and on diabetes compli-
cations are not known (Diabetes UK 2018). Further
studies will no doubt address some of these questions
but presently it is important that healthcare profes-
sionals proceed with some caution when implementing
formula diets in clinical practice.
Summary
The use of formula VLEDs and LEDs has been shown
to effectively produce clinically significant weight loss
of between 10% and 15% bodyweight for up to
12 months, and when combined with weight loss
maintenance strategies can aid long-term weight
maintenance for up to 4 years. Evidence has also
grown for their effective use in obesity-related co-
morbidities, particularly OSA and OA. Recent data
showing that T2D can be put into remission using a
formula LED in up to 46% of people may well
change the landscape of T2D treatment in the coming
few years.
Despite data demonstrating the effectiveness, safety
and patient adherence and acceptability of VLEDs and
LEDs, these dietary strategies are still being underuti-
lised by healthcare professionals in clinical practice.
The exact reasons for this are not well established,
though may relate to healthcare professionals feeling
that they lack the training and resources to put for-
mula diets into practice and that it is outside their
scope of practice. In addition, historical opinions of
formula VLEDs and LEDs that they taste unpleasant
are impossible to adhere to, result in weight regain,
cost too much and have unacceptable side effects may
also influence their use. The evidence base does not
support these opinions and barriers clearly need to be
broken down by educating healthcare professionals
about the science in this area.
It is important to note that VLEDs and LEDs
should be used as part of a multicomponent and mul-
tidisciplinary approach including physical activity,
behaviour change and medical supervision (NICE
2014b). Prior to commencing a formula diet, a medi-
cal, dietetic and psychological assessment should ide-
ally be done. It is evident that there is individual
variability in success with formula diets and there is
also variation in the metabolic response to weight loss
with VLEDs and LEDs. Therefore, the setting of real-
istic expectations is key to avoiding disappointment
and undue feeling of failure in the patient. Although
some factors associated with a positive response to
formula diets have been identified, more research is
needed to fully establish how this dietary method
could be best utilised within clinical practice.
Despite the gaps in knowledge, the current scientific
evidence indicates that the use of formula VLEDs and
LEDs with appropriate medical and dietetic support
should now be considered a treatment option for T2D
remission in those with recently diagnosed T2D, in
those with obesity and in those with selected obesity-
related co-morbidities.
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